Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (775)	4/19/2002 10:32:13 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

The current treatments for acid reflux disease are proton pump inhibitors, such as Losec™, Prilosec™ and Nexium™, but the FDA only approved this class of therapeutics for short-term usage. We are focusing our efforts on a particular serotonin receptor for discovery of novel therapeutic agents that would support long-term usage. A previous drug that targeted the same serotonin receptor proved effective and initially successful on the market, but was later withdrawn from the market due to safety problems related to toxicity. Using our Physiogenomics technology, we have developed the means to detect this toxicity and eliminate it from our drug candidates. Our lead compound, AXM-52402 has in vitro efficacy comparable to the previous drug, with no detectable toxicity.